https://twitter.com/EricTopol/status/1779898447224844527
This month, two phase 2 trial results published: Roche's alpha-synuclein targeting prasinezumab showed motor benefits in some subgroups, and repurposing of lixisenatide might slow down the progression of motor symptoms.
Nah, it is complex question, as there are already approved treatments for Parkinson's. This article summarizes which treatments are approved by FDA. Genetix shall solve nothing for this disease. So far the treatments (either drugs or specific surgery implants) aim to reduce the motoric symptoms, while none of them can claim to reverse the process behind this disease. Also, consider that there are multiple mechanisms at play, and probably the entity itself (Parkinsons disease) shall be changed to reflect all of the new findings and possibilities for halting those mechanisms...
@d_c_ thanks for the link, i was aware there were treatments, this was more for an FDA approved cure, as unlikely as it might seem.